Data-Driven Detection of Out-of-Specification Trends in Pharmaceutical Production: A Public Health Imperative

Abstract

Ensuring the consistent quality of pharmaceutical products is central to public health protection, as undetected deviations in production can translate into substandard medicines reaching patients. This study examined the effectiveness of data analytics in detecting out-of-specification (OOS) trends in pharmaceutical production, with the objective of strengthening quality assurance systems and mitigating downstream public health risks. A quantitative longitudinal design was adopted, drawing on 1,248 pharmaceutical production batches and 9,732 critical quality observations extracted from manufacturing execution and laboratory information management systems. Descriptive analysis indicated that 93.8% of observations remained within specification limits, while 6.2% were classified as out-of-trend (OOT) and 0.9% were confirmed as OOS events. Statistical process control (SPC) flagged 214 instances of process instability, and predictive analytics successfully anticipated 79 of 87 OOS cases, yielding a detection accuracy of 92.1%, compared with 79.4% achieved through traditional monitoring methods. Multivariate modelling further enhanced analytical performance, raising sensitivity to 85.3% and increasing variance explained to 68.5%, relative to 51.2% under univariate approaches. Predictive models also demonstrated a lead detection advantage of 3.4 batches, with sensitivity and specificity values of 91.5% and 92.8%, respectively. Secondary analyses revealed meaningful variability across production lines, with OOT frequencies ranging from 4.7% to 8.9% and 62.5% of deviations clustering within specific operational periods, suggesting systemic rather than random origins. Regression findings identified temperature variation (effect size = 0.61) and mixing time (effect size = 0.48) as the most influential predictors of deviation occurrence, while visualization of impurity profiles revealed variability increases of up to 14.6%. Collectively, these findings confirm that integrated data analytics substantially enhances early detection, reduces false negatives, and improves overall process control in pharmaceutical manufacturing. The study supports the adoption of advanced analytical systems, encompassing SPC, predictive modelling, and multivariate diagnostics, as a strategic mechanism for strengthening quality assurance and, by extension, safeguarding public health.